Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Ephraim P. Hochberg et al.|The Lancet Haematology|2019Cited by 72
Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL PatientsMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|Blood|2016Cited by 17
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E. Ahn, Matthew S. Davids, Danielle M. Brander et al.|Blood Advances|2024Cited by 12
A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL PatientsMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|Blood|2017Cited by 10
Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic LeukemiaMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|Blood|2021Cited by 4